We are pleased to invite investors and analysts to participate in our virtual event on Monday, 14 June 2021, highlighting Roche data presented during the congress scientific program from June 7 – 11 2021.
16:00 – 17:00 CEST / 15:00 - 16:00 BST
10:00 – 11:00 am EDT / 7:00 – 8:00 am PDT
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 3pm CEST on the day of the event. > click here
Agenda - JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam
RAINBOWFISH: A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA)
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
- Q&A
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
Paulo Fontoura, M.D. Ph.D., Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development
Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
Kavita Patel, Lifecycle Leader SMA, Global Product Strategy
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via > ir.roche.com
|
